AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06756347 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patients receiving landmark-based brachial plexus blocks
Description: The operator will visualize anatomical structures in real time, identify the brachial plexus (supraclavicular approach), and guide the needle to the injection site under direct ultrasound visualization
Study NCT06756347 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Landmark-Based Brachial Plexus Block
Description: The operator will identify anatomical landmarks (e.g., interscalene groove, supraclavicular fossa) using palpation and surface anatomy. The needle will be inserted based on these landmarks, with no direct visualization of internal structures.
Study NCT06756347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: injected in both group as local anesthetic agent ( at a standardized concentration and volume) to ensure comparability.
Study NCT04276155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-systematic prescription of anticoagulant therapy
Description: the prescription of anticoagulant is managed by an implantable device follow up
Study NCT06217419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radio Frequency IDentification (RFID) device
Description: RFID devices monitor breathing patterns by means of temperature measurements of the respiratory airflow. The temperature gradient of the air flow in and out of the airways can be correlated to the flow-based respiratory patterns. Accordingly, a temperature-based breath monitoring can be achieved by means of on-skin RFID sensors attached below the nose. Finally, a bilateral measurement of nostrils respiratory flow can provide more information since nasal cavities do not behave in the same way during a respiratory cycle.~In this project we will evaluate the possibility to perform domestic breath flow analysis by exploiting thin, lightweight and battery-less sensing plasters directly attached under the nose. The system includes a proper external reader interrogating the face sensors that is capable to directly communicate with smartphone/pc/tablet/cloud environment.
Study NCT05618093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive hemodynamic measurements
Description: A patient profile will be set up in the Edwards EV1000 clinical platform by inputting the patient's demographic information. One or two Edwards ClearSight finger cuffs will be placed on the index, middle, and/or ring finger on one hand of the patient. A pressure controller will be secured by a forearm strap where the finger cuffs will be connected to the pressure controller. The pressure controller will be connected to the Edwards EV1000 clinical platform monitor. A heart reference sensor (HRS) will be connected to the pressure controller, a finger cuff, and to the patient at heart level. The Edwards EV1000 clinical platform will calibrate the finger probes, then record measurements for 10-30 seconds. If two finger probes are available, measurements will alternate between fingers.
Study NCT05154760 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training, diaphragmatic breathing exercise, core exercises
Description: An exercise program consisting of pelvic floor muscle training, diaphragmatic breathing exercise and core exercises will be applied to the patients.
Study NCT06088160 — intervention group
Intervention type: PROCEDURE
Intervention: Total Hip Arthroplasty
Description: Total hip arthroplasty is a common surgical procedure performed in people with advanced hip osteoarthritis
Study NCT05906524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD6001
Description: KD6001 will be administered intravenously.
Study NCT05906524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be administered intravenously.
Study NCT05906524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously.
Study NCT04935684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Patients randomized in the FMT group will received FMT within 4 weeks following neutrophils recovery after the allo-HSCT procedure. The stool transplant will be done by enema. The day before FMT, patient will undergo bowel cleansing by ingestion of two liters of polyethylene glycol solution. The day of FMT, a colon cleanse enema will be performed in the morning and FMT will be delivered around two hours after the cleanse enema. This colic preparation is essential to optimize the results of FMT.~The enema (50g of stools diluted in 250mL of NaCl 0.9%) will be performed by a qualified member of the study team (nurse) by using a rectal cannula (within 6 hours of thawing). The enema will have to be kept by the patient for as long as possible and at least 30 minutes.
Study NCT04284059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo, vitamin AD and vitamin D are identical in the appearance to guarantee blind. The patients need to administrate 3 capsules once a day for 8 weeks.
Study NCT04284059 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin AD
Description: A vitamin AD capsule contains vitamin A 2000 IU and vitamin D 700 IU. The patients need to administrate 3 capsules once a day for 8 weeks.
Study NCT04284059 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: A vitamin D capsule contains vitamin D 400 IU. The patients need to asministrate 6 capsules/time, once a day for 2 weeks, then change to 5 capsules/time, once a day for 6 weeks.
Study NCT05114278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject
Description: Experimental group will receive intravenous iron infusion (Ferinject©: 15 mg/kg in NaCl solution IV) at randomization, 2weeks after randomization, 4weeks after randomization, and then every month for a total of one year. Comparison group will not receive any intravenous treatment. Both experimental and comparison groups will receive an oral iron supplementation (100 mg/day).
Study NCT05114278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral iron
Description: All patients will receive an oral iron supplementation (100mg/day).
Study NCT05042960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brightness
Description: Changing the colors or brightness on the device (computer screen) for one month
Study NCT05114278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral iron
Description: All patients will receive an oral iron supplementation (100mg/day).
Study NCT05059964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit Training program
Description: The 4 weeks Circuit Training program, it will be of 3 times per week. Each CT workout includes 6 stations per circuit Training. Before the training period, all participants underwent an exercise familiarization session to ensure proper execution of technique.~The 6 stations will be included as 40 lb. carry for 100 ft., 3-min stair climb, 45 s plank pose, 20 lb. carry with a fast walk for 100 ft., right and left single leg stands for as long as balance was maintained, and a 15 lb. carry up and down 30 stairs
Study NCT05059964 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous aerobic exercise Group
Description: Continuous aerobic exercise Frequency 3 time per week Intensity 50% of Heart rate reserve Type continuous aerobic exercise Time 40 minutes
Study NCT05729139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab-Rwlc
Description: 350 mg via IV infusion over 30 minutes every 3 weeks for up to two years
Study NCT05729139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2a
Description: Self-administered by the participant via subcutaneous injection in the abdomen or thigh weekly for up to one year. Participants will receive one of three doses:~Dose level 0: 45 mcg~Dose level 1: 90 mcg~Dose level 2: 135 mcg~Dose level 0 is considered the starting dose and sequential cohorts of three participants will be treated with escalated doses until the maximum tolerated dose is established.
Study NCT06326658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bufei Yishen Prescription Granule
Description: The comparison group was given Bufei Yishen Prescription Granule.The course of treatment was the same as that of the experimental group.
Study NCT06326658 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bufei Yishen Prescription Granule
Description: The comparison group was given Bufei Yishen Prescription Granule.The course of treatment was the same as that of the experimental group.
Study NCT05238324 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetic HMI-203
Description: HMI-203 delivered intravenously
Study NCT05057377 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standard Overground Assessment
Description: The standard overground methods to assess three main components of walking are the 10 Meter Walk Test (meters/second, used to measure speed), 5x Sit-to-Stand (seconds, used to measure strength), and the 6-Minute Walk Test (meters, used to measure endurance).
Study NCT05057377 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Robotic Safety-Environment Assessment
Description: The methods for assessment of the three main components of walking in the robotic environment will be the maximum walking speed tolerated (meters/second, to measure speed), deadband resistance (kilograms, to measure strength), and the 6-minute walk test (meters, to measure endurance).
Study NCT05284383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Closed-label nocebo conditioning
Description: Conditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of a Transcutaneous Electrical Nerve Stimulation (TENS) device (CS) will be repeatedly paired with a moderate intensity pressure pain stimulus, whereas a message indicating the deactivation of the sham device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the conditioning procedure (i.e. activation of the device will increase their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test for a nocebo effect (i.e. to test whether participants score TENS on trials as more painful than TENS off trials).
Study NCT05284383 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Closed-label nocebo conditioning
Description: Conditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of a Transcutaneous Electrical Nerve Stimulation (TENS) device (CS) will be repeatedly paired with a moderate intensity pressure pain stimulus, whereas a message indicating the deactivation of the sham device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the conditioning procedure (i.e. activation of the device will increase their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test for a nocebo effect (i.e. to test whether participants score TENS on trials as more painful than TENS off trials).
Study NCT05284383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Closed-label counterconditioning
Description: Counterconditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of the TENS device (CS) is now repeatedly paired with a non-painful intensity pressure pain stimulus, whereas a message indicating the sham deactivation of the TENS device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a verbal suggestion in line with the counterconditioning procedure (i.e. activation of the device will reduce their pain). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials or even score TENS on trials as less painful).
Study NCT05284383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open-label counterconditioning
Description: Counterconditioning consists of a learning and test phase. In the learning phase, a message indicating the sham activation of the TENS device (CS) is now repeatedly paired with a non-painful intensity pressure pain stimulus, whereas a message indicating the sham deactivation of the TENS device will be repeatedly paired with a slightly painful pressure pain stimulus. Participants will be given a open-label verbal suggestions in line with the counterconditioning procedure (i.e. they are told counterconditioning will be used to reduce nocebo effects and they are told the device is sham, but that their pain will still be influenced because of the placebo effect). The testing phase is similar to the learning phase, but a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials or even score TENS on trials as less painful).
Study NCT05284383 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Closed-label extinction
Description: Extinction consists of a learning and test phase. In the learning phase, slightly painful stimuli are used for all trials. During the testing phase, again a slight pressure pain intensity is used for all trials, to test whether the nocebo effect is successfully reduced (i.e. to test whether participants no longer score TENS on trials as more painful than TENS off trials).
Study NCT05504928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School nurse program
Description: School nurse program providing health care through assessment, intervention and follow-up of group A β-hemolytic streptococcal pharyngitis and facilitation of secondary antibiotic prophylaxis for children with latent rheumatic heart disease.
Study NCT06320964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TARANG
Description: For newly married women, the intervention had one introductory rapport-building session, followed by 16 group sessions facilitated by trained female moderators over 5 months. The intervention aimed to empower participants by enhancing their understanding of fundamental topics such as menstruation, conception, and contraception, choice of a method among others. Sessions also covered topics to strengthen participants' sense of agency and their ability to make informed decisions regarding family planning and the timing of their first childbirth. Similarly, for husbands, a male moderator delivered sessions on four topics: Love, Relationships and Expectations; Conception and Health; Contraception Methods, and how to choose family planning methods. For MILs, a female moderator covered four sessions: Nutrition flag, Conception and Health, communication between family members, and the final session on relationships with daughter-in-law.
Study NCT05539742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coconut oil
Description: Coconut oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits.
Study NCT06105359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dignity therapy
Description: Dignity therapy will be applied in the interview room that will be requested in the oncology clinic to protect the confidentiality of information.~The application is planned as five sessions and the sessions will last approximately 40 minutes. Two questions in the dignity therapy protocol will be discussed in each session.
Study NCT06105359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standardize care
Description: Patients in this group will receive standard treatment and care in the clinic. No action will be taken other than standard care.
Study NCT05539742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Palm oil
Description: Palm oil will be given to each participant in the amount of 40 g, which will be incorporated into biscuits.
Study NCT04984252 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-compassion comprising compassionate body scan-1, compassion body scan-2 and short noticing practice
Description: This intervention includes 3 short meditations that are identified as the active component in the previous study (ID: NCT04665167)
Study NCT04984252 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Self-compassion comprising self-compassion break, loving kindness meditation, and breathing exercise.
Description: This intervention includes 3 short meditations that are identified as the inactive component in the previous study (ID: NCT04665167)
Study NCT06105359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standardize care
Description: Patients in this group will receive standard treatment and care in the clinic. No action will be taken other than standard care.
Study NCT00980304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT05135611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 channel Electrical Stimulation Device
Description: electrical stimulation at muscles which related with sleep apnea,. 4-channel NMES is the protocol that provides sequential electrical stimulation to Rt. suprahyoid m (channel 1), Lt.suprahyoid m (channel 2), bilateral thyrohyoid m (channel 3), and biltateral sternothyroid m (channel 4). At this time, channels 1 and 2 start to contract first and stimulate for 1200ms, and channel 3 starts stimulation 150ms after channels 1 and 2, and applies stimulation for 1050ms. Channel 4 starts stimulation 250ms after stimulation of channels 1 and 2 and stimulates it for 950 ms.
Study NCT05262686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belimumab
Description: Belimumab was intravenously administrated at a dose of 10mg/kg once a month for at least 24 weeks.
Study NCT05262686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab was intravenously administrated at a dose of 10mg/kg once a month for at least 24 weeks.
Study NCT05262686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.
Study NCT05262686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-2
Description: Low lose interleukine-2 at a dose of 1 million IU was injected once every other day for 12 weeks, then the same dose of IL2 was injected once a week at the second stage for 12 weeks.
Study NCT01958892 — intervention group
Intervention type: PROCEDURE
Intervention: TURP, TUERP
Study NCT04901416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DVX201
Description: Based upon the occurrence of DLT (does limiting toxicity), the MTD will be estimated as the highest dose at which the toxicity probability is the closest to the target probability (denoted pT=0.30) following up to 2 doses of DVX201. The corresponding dose allocation methodology is a modified toxicity interval design based upon (Ji et al., 2010; Ji et al., 2013).~All patients who have at least one dose initiated will be included in the safety analysis. Patients who are enrolled but never exposed to investigational product will be replaced for all analyses. Patients who get exposed to lymphodepleting chemotherapy will be followed and reported for outcomes overall, but for determination of safety and efficacy, only those subjects who have been exposed to the investigational agent will be included.
Study NCT04546555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual chamber pacemaker
Description: Dual chamber pacemaker implantation with Bachmann's bundle lead and His bundle lead placement.
Study NCT04546555 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dual chamber pacemaker
Description: Dual chamber pacemaker implantation with Bachmann's bundle lead and His bundle lead placement.
Study NCT04546555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated Physiologic Pacing
Description: The lower rate limit will be programmed to an individualized heart rate.
Study NCT04546555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nocturnal Pacing
Description: In addition to adjustment of the lower rate limit to an individualized heart rate, nocturnal pacing a moderate HR elevation of 110bpm will be implemented between 8pm and 6am.
Study NCT04984252 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Distraction group
Description: Participants will be asked to listen recording on irrelevant topic.
Study NCT05613933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Improved practices
Description: A package of tools including: antibiotic prophylaxis guidelines reminders, periodic reminders, the Infectious Endocarditis Prevention Card for patients at risk, practical information targeting both dentists and patients, etc...
Study NCT06040281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intensive individual support in nutrition and exercise
Description: Intensive care for nutrition and exercise adapted to the social context. Individualised exercise and nutrition recommendations.~three weeks of inpatient rehabilitation with an individual plan of treatment, which includes medical care, sports therapy, physiotherapy, ergotherapy, nutritional education and psychological care App access for comprehensive information about dialysis (nutrition, travel, medication, etc.)
Study NCT06040281 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care App access for comprehensive information about dialysis (nutrition, travel, medication, etc.)
Study NCT04272333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motolimod
Description: Intratumoral microdose injection by the CIVO device.
Study NCT04272333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intratumoral microdose injection by the CIVO device.